US/UK/Canada

Share

Quotes

“We are pleased to receive orphan drug designations for ONCOS-102 from the two leading regulatory agencies in the world. They confirm the need for developing novel therapies for severe cancer forms such as ovarian cancer.″
Frans Wuite, M.D., President and Chief Executive Officer of Oncos Therapeutics
Pick a time period -
Tags ( Active)

Targovax appoints two new directors to its board

Oslo, 14 September 2015: Targovax AS (NOTC: TRVX, “Targovax”) is pleased to announce that EvaLotta Allan and Diane Mellett were today elected as new non-executive directors at the extraordinary general meeting of Targovax.Eva-Lotta Allan has more than 25 years of business development experience from the biotechnology and life science industry in both private and public companies. She has significant operational and investor relations expertise as well as board experience. Ms Allan currently holds the position as Chief Business Officer at Immunocore Ltd, an immune-oncology company

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology

Contemplate a private placement of NOK 125–150 million to fund the combined business Oslo, (11 June 2015): Targovax AS (“Targovax” or the “Company”) has entered into an agreement with the shareholders of Oncos Therapeutics Oy (“Oncos”) to acquire the shares of Oncos with settlement in Targovax shares (the “Transaction”). The combined company with multiple assets in research and development will be a Nordic leader within immuno-oncology. The new company will have a strong senior management team and be financially backed by reputable institutional investors with sector specialist HealthCap

ONCOS-102 granted US lung cancer orphan drug designation

Oncos Therapeutics’ lead compound now has three orphan drug designations in the US and Europe HELSINKI, Finland, January 12, 2015—Oncos Therapeutics Ltd., a company developing novel cancer immune therapies, announced today that the US Food and Drug Administration (FDA) has granted an orphan drug designation for its lead compound ONCOS-102 in the treatment of malignant mesothelioma.Malignant mesothelioma is a rare but aggressive cancer mostly located in the pleura, the lining of the lung. The prognosis is poor with a median overall survival of 12 months. Limited progress has been made

Oncos Therapeutics recruits Dr Magnus Jaderberg as CMO to strengthen its focus on cancer immunotherapy

HELSINKI, Finland, June 4, 2014—Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Dr Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer (CMO).Dr Jaderberg is a pharmaceutical physician with more than 25 years’ experience in various R&D functions, including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. His therapeutic area expertise includes immunology, oncology and infectious diseases. Dr Jaderberg has experience of all phases of clinical

Oncos Therapeutics granted US and EU Orphan Drug Designation for ONCOS-102 in ovarian cancer

HELSINKI, Finland, June 2, 2014—Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan Drug Designation to the company’s lead compound ONCOS-102 for the treatment of ovarian cancer.“We are pleased to receive orphan drug designations for ONCOS-102 from the two leading regulatory agencies in the world. They confirm the need for developing novel therapies for severe cancer forms such as ovarian cancer″, said Frans Wuite, M.D., President

Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

-- Phase I Study of ONCOS-102 in Late-stage Refractory Cancer Patients Successfully Completed and Presented at CIMT Annual Meeting --Mainz, Germany 8th May 2014 - Oncos Therapeutics, Ltd., a clinical stage biotechnology company specializing in the development of targeted cancer immunotherapeutics, presented Phase 1 clinical data demonstrating that local administration of its lead compound, ONCOS-102, is able to induce a systemic, tumor-specific immune response in late-stage cancer patients. The data were presented in two separate podium presentations on May 7th and 8th at the Annual Meeting

There are no items matching the current filter
There are no more items matching the current filter
Back to top